{"prompt": "['countries will be defined as the time at which the primary endpoint of OS has been met.', '17.7 Movember Discontinuation Criteria', 'Premature termination of this study may occur because of a regulatory authority decision, change in opinion of', 'the IRB/IEC, intervention safety problems, or at the discretion of Movember. If study is prematurely terminated', 'or discontinued, Movember will promptly notify the Investigator. After notification, the Investigator must notify', 'the respective IRB/IEC, and contact all participating subjects within a 4-week time period. As directed by', 'Movember, all study materials must be collected and all CRFs completed to the greatest extent possible.', '17.8 Publications', 'Publication of study results is discussed in the Clinical Trial Agreement. Details regarding production of', 'manuscripts and conference presentations will adhere to the International Committee of Medical Journal Editors', '(ICMJE) requirements for authorship and contributorship. http://www.icmje.org/ethical_1author.htm', 'INTERVAL Protocol Version 4.0, 19 April 2018', '55']['18.0 REFERENCES', '1.', 'Halabi S, Lin CY, Kelly WK, et al. Updated prognostic model for predicting overall survival in first-line', 'chemotherapy for patients with metastatic castration-resistant prostate cancer. Journal of clinical', 'oncology : official journal of the American Society of Clinical Oncology. Mar 1 2014;32(7):671-677', '2.', 'Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer', 'diagnosis in the health professionals follow-up study. Journal of clinical oncology : official journal of the', 'American Society of Clinical Oncology. Feb 20 2011;29(6):726-73', '3.', 'Lynch ME, Brooks D, Mohanan S, et al. In Vivo tibial compression decreases osteolysis and tumour', 'formation in a human metastatic breast cancer model. Journal of bone and mineral research : the', 'official journal of the American Society for Bone and Mineral Research. May 3 2013.', '4.', 'Galvao DA, Nosaka K, Taaffe DR, et al. Resistance training and reduction of treatment side effects in', 'prostate cancer patients. Medicine and science in sports and exercise. Dec 2006;38(12):2045-2052.', '5.', 'Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise', 'program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer', 'without bone metastases: a randomized controlled trial. J Clin Oncol. Jan 10 2010;28(2):340-347.', '6.', 'Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous', 'chemotherapy. The New England journal of medicine. Jan 10 2013;368(2):138-148', '7.', 'Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in Metastatic Prostate Cancer before', 'Chemotherapy. The New England journal of medicine. Jun 1 2014.', '8.', 'MacKelvie KJ, Taunton JE, McKay HA, Khan KM. Bone mineral density and serum testosterone in', 'chronically trained, high mileage 40-55 year old male runners. British journal of sports medicine. Aug', '2000;34(4):273-278.', '9.', 'Hvid T, Winding K, Rinnov A, et al. Endurance training improves insulin sensitivity and body', 'composition in prostate cancer patients treated with androgen deprivation therapy. Endocrine-related', 'cancer. Oct 2013;20(5):621-632.', '10.', 'Hawkins VN, Foster-Schubert K, Chubak J, et al. Effect of exercise on serum sex hormones in men: a', '12-month randomized clinical trial. Medicine and science in sports and exercise. Feb 2008;40(2):223-', '233.', '11.', 'Zimmer P, Jager E, Bloch W, Zopf EM, Baumann FT. Influence of a six month endurance exercise', 'program on the immune function of prostate cancer patients undergoing Antiandrogen- or', 'Chemotherapy: design and rationale of the Prolmmun study. BMC cancer. 2013;13:272.', '12.', 'Matsumoto AM, Bremner WJ. Serum testosterone assays--accuracy matters. The Journal of clinical', 'endocrinology and metabolism. Feb 2004;89(2):520-524.', '13.', 'Stark JR, Li H, Kraft P, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate', 'cancer incidence and mortality. Int J Cancer. Jun 1 2009;124(11):2683-2689.', '14.', 'Nicklas BJ, Hsu FC, Brinkley TJ, et al. Exercise training and plasma C-reactive protein and interleukin-6', 'in elderly people. J Am Geriatr Soc. Nov 2008;56(11):2045-2052.', '15.', 'Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer', 'promotion. Hormone molecular biology and clinical investigation. Jan 1 2015;21(1):57-74.', '16.', 'Ismail HA, Lessard L, Mes-Masson AM, Saad F. Expression of NF-kappaB in prostate cancer lymph', 'node metastases. The Prostate. Feb 15 2004;58(3):308-313.', '17.', 'Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with', 'clinicopathological features and patient survival in patients with prostate cancer. British journal of', 'cancer. Jun 14 2004;90(12):2312-2316.', '18.', 'Rhee H, Gunter JH, Heathcote P, et al. Adverse effects of androgen-deprivation therapy in prostate', 'cancer and their management. BJU international. Apr 2015;115 Suppl 5:3-13.', '19.', 'Flanagan J, Gray PK, Hahn N, et al. Presence of the metabolic syndrome is associated with shorter', 'time to castration-resistant prostate cancer. Annals of oncology : official journal of the European Society', 'for Medical Oncology/ESMO. Apr 2011;22(4):801-807.', '20.', 'Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and', 'INTERVAL Protocol Version 4.0, 19 April 2018', '56']\n\n###\n\n", "completion": "END"}